March 19, 2021 09:30 AM EDTUpdated 01:37 PM

Gone away are the bluebird execs as COO, CMO both leave the nest; Mike Nally is latest major figure to move on from Merck

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ As bluebird bio’s regulatory concerns swell yet again by pressing the pause button for LentiGlobin a month ago, Joanne Smith-Farrell won’t be around to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gone away are the bluebird execs as COO, CMO both leave the nest; Mike Nally is latest major figure to move on from Merck

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Gone away are the blue­bird ex­ecs as COO, CMO both leave the nest; Mike Nal­ly is lat­est ma­jor fig­ure to move on from Mer­ck

Copy Chief

Editor

Sign up to read this article for free.

Gone away are the bluebird execs as COO, CMO both leave the nest; Mike Nally is latest major figure to move on from Merck